Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India
The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share.
Emcutix Biopharmaceuticals Limited, a subsidiary of Emcure Pharmaceuticals, has entered an exclusive in-licensing agreement with WiQo, an Italian derma-cosmetic and medical device company, to introduce PRX-PLUS to the Indian market. This strategic partnership grants Emcutix the rights to import, promote, distribute, and sell PRX-PLUS, a non-invasive skin treatment that utilizes a unique deep-impacting formula for instant skin tightening. WiQo's patented formulas are already used by over 40,000 dermatologists and aesthetic doctors worldwide, with over 8 million needle-free skin booster procedures performed since 2011, highlighting the global success of their innovative approach.
The introduction of PRX-PLUS is poised to capitalize on the rapidly growing Indian dermatology market, which is estimated at $1.8 billion USD with a projected growth rate of 11-12 per cent. PRX-PLUS offers a safe, pain-free alternative to traditional aesthetic treatments, suitable for all skin types and seasons, and features a droplet-based skincare solution promoting immediate skin lifting without injections or downtime. This collaboration signifies Emcutix’s commitment to expanding its portfolio of prescription and consumer dermatology solutions in India, addressing the increasing demand for effective and convenient skincare options driven by rising disposable incomes and heightened skincare awareness.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
Emcure Pharmaceuticals Ltd., established in 1981, operates as a global pharmaceutical manufacturer and marketer, offering a diverse portfolio of pharmaceutical and biopharmaceutical products. Their offerings span various dosage forms, including oral solids and liquids, injectables (both lIPOsomal and lyophilized), biotherapeutics, and complex APIs, addressing major therapeutic areas such as gynaecology, cardiology, oncology, and HIV. With over 350 brands and a distribution network covering more than 70 countries, Emcure has established a significant international presence.
The company has a market cap of over Rs 20,000 crore. The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share. Investors should keep an eye on this mid-cap pharma stock.
Disclaimer: The article is for informational purposes only and not investment advice